Hikma's nationwide US ciprofloxacin tablet recall follows impurity result above FDA guide level
The FDA has logged a Class II, still-open recall of Hikma's US ciprofloxacin tablets, but the entry gives no volumes, so the commercial hit cannot yet be sized.
11 Nov 2026 · FDA enforcement report · Regulator
Hikma Pharmaceuticals USA is recalling ciprofloxacin tablets across the United States, according to the FDA's enforcement report of 11 November 2026. The action is logged as D-0165-2027, classed as Class II, and was still open when the report was published.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Official record: FDA enforcement report ↗
Written by CompePharma's editorial system from the official record. AI-assisted; check the source before acting. Not investment advice.
More Manufacturing & supplyAll →
Manufacturing & supply
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
18 Nov 2026 · Health Canada · Regulator
Manufacturing & supply
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
18 Nov 2026 · Health Canada · Regulator
Manufacturing & supply
Health Canada: Raz Design recalls shower commode chairs over seats that can break
18 Nov 2026 · Health Canada · Regulator
Manufacturing & supply
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
18 Nov 2026 · Lantern Pharma Inc. LTRN · Company news
Manufacturing & supply
OXB confirms manufacturing deal with Aura Biosciences for bel-sar Phase 3 and commercial supply
17 Nov 2026 · OXB · Company news
Manufacturing & supply
Diagnostica Stago recalls lot of STHEMO DDi M, Dutch inspectorate notice shows
17 Nov 2026 · IGJ · Regulator